{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:55:37Z","timestamp":1790603737341,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MR\/K01532X\/1"],"award-info":[{"award-number":["MR\/K01532X\/1"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S007555\/1"],"award-info":[{"award-number":["MR\/S007555\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K01532X\/1"],"award-info":[{"award-number":["MR\/K01532X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225198\/Z\/22\/Z"],"award-info":[{"award-number":["225198\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["200838\/Z\/16\/Z"],"award-info":[{"award-number":["200838\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220171\/Z\/20\/Z"],"award-info":[{"award-number":["220171\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222426\/Z\/21\/Z"],"award-info":[{"award-number":["222426\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["MR\/V031635\/1"],"award-info":[{"award-number":["MR\/V031635\/1"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.celrep.2025.116418","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:04:30Z","timestamp":1760144670000},"page":"116418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interplay of host and viral genetic variations in modulating antibody responses to genotype 3a hepatitis C virus: Implications for vaccine design"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9757-5382","authenticated-orcid":false,"given":"Zhiqing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Quistrebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiting","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Nisioi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan K.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"McKeating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-0823","authenticated-orcid":false,"given":"Alexander W.","family":"Tarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-8353","authenticated-orcid":false,"given":"M. Azim","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2025.116418_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/13596535211072672","article-title":"The curing regimens of HCV: A SWOT analysis","volume":"27","author":"Cornberg","year":"2022","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.celrep.2025.116418_bib2","article-title":"Hepatitis C Virus Vaccine: Challenges and Prospects","volume":"8","author":"Duncan","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.celrep.2025.116418_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.chom.2018.10.012","article-title":"Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection","volume":"24","author":"Kinchen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2025.116418_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cld.2008.03.008","article-title":"Hepatitis C virus entry and neutralization","volume":"12","author":"Stamataki","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.celrep.2025.116418_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000310","article-title":"Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains","volume":"5","author":"Dreux","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2025.116418_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.celrep.2025.116418_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1099-1654(200003\/04)10:2<101::AID-RMV268>3.0.CO;2-W","article-title":"The role of the hepatitis C virus glycoproteins in infection","volume":"10","author":"Flint","year":"2000","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib8","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.01888-08","article-title":"Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection","volume":"83","author":"Liu","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.26733","article-title":"Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry","volume":"59","author":"Douam","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.celrep.2025.116418_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.abn9884","article-title":"Structure of the hepatitis C virus E1E2 glycoprotein complex","volume":"378","author":"Torrents de la Pena","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.celrep.2025.116418_bib11","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jhep.2019.01.033","article-title":"A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors","volume":"70","author":"Banda","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116418_bib12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41586-024-07783-5","article-title":"The hepatitis C virus envelope protein complex is a dimer of heterodimers","volume":"633","author":"Augestad","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.116418_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.celrep.2025.116418_bib14","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2025.116418_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4254\/wjh.v7.i6.831","article-title":"Hepatitis C virus genetic variability and evolution","volume":"7","author":"Echeverria","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116418_bib16","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.celrep.2025.116418_bib17","doi-asserted-by":"crossref","first-page":"veab065","DOI":"10.1093\/ve\/veab065","article-title":"Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a","volume":"7","author":"Lin","year":"2021","journal-title":"Virus Evol."},{"key":"10.1016\/j.celrep.2025.116418_bib18","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1128\/JVI.01332-10","article-title":"Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype","volume":"85","author":"Tarr","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.05.029","article-title":"Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia","volume":"73","author":"Nguyen","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116418_bib20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2025.116418_bib21","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1038\/s41467-021-25649-6","article-title":"Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure","volume":"12","author":"Smith","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.116418_bib22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.celrep.2025.116418_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","article-title":"Genotype 3 Infection: The Last Stand of Hepatitis C Virus","volume":"77","author":"Chan","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.celrep.2025.116418_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2018.09.005","article-title":"Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies","volume":"160","author":"Tarr","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.celrep.2025.116418_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/gutjnl-2021-326323","article-title":"Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice","volume":"72","author":"Alzua","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.celrep.2025.116418_bib26","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1038\/s41467-022-34961-8","article-title":"Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate","volume":"13","author":"Sliepen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.116418_bib27","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1128\/JVI.02700-15","article-title":"A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance","volume":"90","author":"Urbanowicz","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2021.10.005","article-title":"An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development","volume":"162","author":"Salas","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2025.116418_bib29","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/12.4.43R","article-title":"Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds","volume":"12","author":"Spiro","year":"2002","journal-title":"Glycobiology"},{"key":"10.1016\/j.celrep.2025.116418_bib30","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3389\/fimmu.2018.00910","article-title":"Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies","volume":"9","author":"Lavie","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2025.116418_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.32772","article-title":"Identification of novel neutralizing determinants for protection against HCV","volume":"77","author":"Alzua","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.celrep.2025.116418_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1159\/000362209","article-title":"Recombinant human L-ficolin directly neutralizes hepatitis C virus entry","volume":"6","author":"Hamed","year":"2014","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.celrep.2025.116418_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s13238-010-0088-9","article-title":"Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry","volume":"1","author":"Brown","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.celrep.2025.116418_bib35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.116418_bib36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.116418_bib37","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1038\/ncomms6699","article-title":"Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes","volume":"5","author":"Terczynska-Dyla","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.116418_bib38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/ng.3836","article-title":"IFN-lambda3, not IFN-lambda4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis","volume":"49","author":"Eslam","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.116418_bib39","article-title":"The Associations of HLA-A\u221702:01 and DRB1\u221711:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population","volume":"6","author":"Huang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2025.116418_bib40","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2025.116418_bib41","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4582","article-title":"Using evolutionary data to make sense of macromolecules with a \u201cface-lifted\u201d ConSurf","volume":"32","author":"Yariv","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.celrep.2025.116418_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.035956-0","article-title":"The role of neutralizing antibodies in hepatitis C virus infection","volume":"93","author":"Edwards","year":"2012","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cei.12962","article-title":"Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56(+) natural killer cell responses in chronic HCV-infected patients","volume":"189","author":"Long","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.celrep.2025.116418_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41467-023-36183-y","article-title":"Regions of hepatitis C virus E2 required for membrane association","volume":"14","author":"Kumar","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.116418_bib46","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1128\/JVI.76.15.7672-7682.2002","article-title":"Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles","volume":"76","author":"Clayton","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib47","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fimmu.2018.01315","article-title":"The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein","volume":"9","author":"Tzarum","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2025.116418_bib48","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.bbapap.2007.12.015","article-title":"Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein","volume":"1784","author":"Iacob","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.celrep.2025.116418_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110859","article-title":"Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening","volume":"39","author":"Pfaff-Kilgore","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2025.116418_bib51","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/JVI.00248-09","article-title":"Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity","volume":"83","author":"Keck","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.116418_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008254","article-title":"Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes","volume":"4","author":"Mancini","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2025.116418_bib54","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.116418_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein","volume":"87","author":"Keck","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007772","article-title":"Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design","volume":"15","author":"Keck","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2025.116418_bib57","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib58","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013359","article-title":"N-linked protein glycosylation in the endoplasmic reticulum","volume":"5","author":"Breitling","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.celrep.2025.116418_bib59","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1074\/jbc.271.11.6363","article-title":"The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency","volume":"271","author":"Shakin-Eshleman","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2025.116418_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1042\/bj3230415","article-title":"Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser\/Thr sequons that are poor oligosaccharide acceptors","volume":"323","author":"Kasturi","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.celrep.2025.116418_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2016.08.006","article-title":"New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase","volume":"134","author":"Fearns","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.celrep.2025.116418_bib62","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42463","article-title":"Interferon lambda 4 impacts the genetic diversity of hepatitis C virus","volume":"8","author":"Ansari","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2025.116418_bib63","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1038\/s41467-021-25218-x","article-title":"Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.116418_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199308","article-title":"A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns","volume":"341","author":"Chumbe","year":"2024","journal-title":"Virus Res."},{"key":"10.1016\/j.celrep.2025.116418_bib65","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib66","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1099\/jgv.0.000537","article-title":"Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay","volume":"97","author":"Urbanowicz","year":"2016","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.celrep.2025.116418_bib67","article-title":"Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation","volume":"97","author":"Guo","year":"2018","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.celrep.2025.116418_bib68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-1-4939-8976-8_19","article-title":"Cloning and Analysis of Authentic Patient-Derived HCV E1\/E2 Glycoproteins","volume":"1911","author":"Urbanowicz","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.celrep.2025.116418_bib69","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-4939-8976-8_30","article-title":"Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp)","volume":"1911","author":"Bailey","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.celrep.2025.116418_bib70","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.celrep.2025.116418_bib71","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/bioinformatics\/bty633","article-title":"ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R","volume":"35","author":"Paradis","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2025.116418_bib72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.2041-210X.2011.00169.x","article-title":"phytools: an R package for phylogenetic comparative biology (and other things)","volume":"3","author":"Revell","year":"2012","journal-title":"Methods Ecol. Evol."},{"key":"10.1016\/j.celrep.2025.116418_bib73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng.3835","article-title":"Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus","volume":"49","author":"Ansari","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.116418_bib74","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.celrep.2025.116418_bib75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725011891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725011891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:01:52Z","timestamp":1790600512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124725011891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2211124725011891"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2025.116418","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interplay of host and viral genetic variations in modulating antibody responses to genotype 3a hepatitis C virus: Implications for vaccine design","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2025.116418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116418"}}